Capacity Bio

capacitybio.com

Capacity Bio is a biotechnology company focused on mitochondrial biology, specifically developing small molecules, peptides, and nanoparticles that enhance the identification of dysfunctional mitochondria and activate mitophagy pathways. Their proprietary approach aims to promote the clearance of dysfunctional mitochondria, addressing challenges in targeting mitophagy safely and effectively. With a recent $35 million financing round, Capacity Bio is advancing its first-in-class mitophagy agonist expected to enter clinical trials in 2024, positioning itself as a leader in the mitophagy therapeutics market.